Clinical trials: Pituitary Adenomas
Pituitary Tumor
PITUItary Carcinoma or Aggressive Tumors REgistry -Lyon
The purpose of this study is to observe predictors of pituitary tumor recurrence and markers of persistent disease activity through computerized collection of comprehensive demographic, therapeutic, pathologic and outcome…
- Trial name
- PITUICARE-Lyon (NCT02854228)
- Where
- France
- Volunteers
- 1,300 people
- Sponsor
- Hospices Civils de Lyon
Invasive Prolactinomas Involving the Cavernous Sinus
Dopamine Agonists Withdrawal Study of Invasive Prolactinomas Involving the Cavernous Sinus
The purpose of this study is to observe whether dopamine agonists can be safely withdrawn after the tumor volume and prolactin level of invasive prolactinomas involving the cavernous sinus have been effectively controlled through…
- Trial name
- NCT02536261
- Where
- 8 sites in China
- Volunteers
- 30 people
- Sponsor
- Zhebao Wu
McCune Albright Syndrome, Polyostotic Fibrous Dysplasia
A Study of the Effects of Pegvisomant on Growth Hormone Excess in McCune-Albright Syndrome
This study will examine the effect of pegvisomant on growth hormone excess in patients with McCune-Albright syndrome (MAS). Patients with this disease have polyostotic fibrous dysplasia-a condition in which areas of normal bone…
- Trial name
- NCT00017927
- Testing
- Pegvisomant
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- National Institute of Dental and Craniofacial Research (NIDCR)
Dementia, Movement Disorders
Comparison of NeuroEXPLORER PET/CT Versus Standard-of-care PET/CT of the Head and Neck Region.
The goal of this clinical study is to compare the current standard-of-care PET/CT scanner with the new NeuroEXPLORER PET/CT, with the aim of demonstrating the added diagnostic value of the new scanner.
- Conditions
- Dementia, Movement Disorders, ALS - Amyotrophic Lateral Sclerosis, Epilepsy
- Trial name
- NCT07595666
- Testing
- Standard-of-care PET/CT, NeuroEXPLORER
- Where
- Belgium
- Volunteers
- 1,600 people, healthy volunteers welcome
- Sponsor
- prof. dr. Koen Van Laere
Pituitary Adenoma
Molecular Imaging of Pituitary Adenomas
Background: Pituitary adenomas affect 10% of the population. Surgery offers the most cost-effective treatment modality but cure rates are only 40-70%, in part due to the limitations of Magnetic Resonance Imaging (MRI) in…
- Trial name
- MIMOPA (NCT03815838)
- Testing
- PET imaging
- Where
- United Kingdom
- Volunteers
- 20 people
- Sponsor
- Cardiff University
Pituitary Diseases
Prognosis of Atypical Pituitary Adenomas
Context: Pituitary adenoma is generally indolent, but an aggressive subtype called atypical adenoma has uncertain prognosis, and an unclear relationship between prognosis and morphology.
- Trial name
- NCT00473369
- Sponsor
- Tohoku University
Pituitary Adenoma
Copeptin as a Diagnostic Marker in the Management of Neurosurgical Patients With Disturbance of Water Homeostasis
Water imbalance and consecutive electrolyte disturbances are common in the postoperative course of neurosurgical patients after pituitary surgery.
- Trial name
- NCT01465672
- Where
- 2 sites in Switzerland
- Volunteers
- 125 people
- Sponsor
- University Hospital, Basel, Switzerland
Cushing's Disease, Corticotroph Adenoma
Study of Cabergoline in Treatment of Corticotroph Pituitary Tumor
This study was designed to check the efficacy of a new oral medical drug treatment, namely Cabergoline, for the treatment of Cushing Disease due to pituitary adenoma. Background: Cabergoline is a Dopamine 2 receptor agonist.
- Trial name
- NCT00889525
- Testing
- Cabergoline
- Where
- India
- Sponsor
- Seth Gordhandas Sunderdas Medical College
Pituitary Adenoma
Multicentric Prospective Validation of the Zurich Pituitary Score
Predictive analytics for GTR, EOR and RV are useful in surgical decision-making, particularly whenever there is no unequivocal indication for surgery. Several factors have been shown to have a role in predicting GTR.
- Trial name
- NCT04076046
- Where
- 10 sites in United States, Austria and 4 more
- Volunteers
- 408 people
- Sponsor
- University of Zurich
Macroprolactinoma
Efficacy of Rapid Escalation of Cabergoline in Comparison to Conventional Dosing in Prolactin Secreting Macroadenomas.
To study the effects of rapid escalation of Cabergoline in comparison to conventional dosing in macroprolactinomas. Rapid escalation of cabergoline may help in earlier normalization of prolactin and shrinkage of tumor mass, and…
- Trial name
- NCT01143584
- Testing
- Cabergoline
- Where
- India
- Volunteers
- 20 people
- Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh
Cushing's Syndrome, Pituitary Adenoma
Defining the Genetic Basis for the Development of Primary Pigmented Nodular Adrenocortical Disease (PPNAD) and the Carney Complex
Lentiginosis refers to groups of diseases marked by the presence of pigmented spots on the skin. These conditions are most commonly associated with multiple tumors and changes in hormone producing glands.
- Conditions
- Cushing's Syndrome, Pituitary Adenoma, Carney Complex, Primary Pigmented Nodular Adrenocortical Disease
- Trial name
- NCT00001452
- Testing
- oCRH
- Where
- United States
- Volunteers
- 1,387 people
- Sponsor
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Surgery, Pituitary Adenoma
Comparative Effectiveness of Different Surgical Approaches for Giant Pituitary Adenomas
The surgical treatment strategy for giant invasive pituitary adenoma is one of the current hot spots in the field of clinical research on pituitary adenoma.
- Trial name
- NCT05448690
- Testing
- Two different approaches, Non-combined approach
- Where
- 13 sites in China
- Volunteers
- 600 people
- Sponsor
- Huashan Hospital
Brain Neoplasm, Glioblastoma
Evaluation of Factors in Human Brain Tumors
Presently, patients with primary malignant brain tumors have a life expectancy of 15 weeks following surgery unless they receive additional types of therapy (chemotherapy, radiotherapy, and/or immunotherapy).
- Conditions
- Brain Neoplasm, Glioblastoma, Glioma, Pituitary Neoplasm
- Trial name
- NCT00001171
- Where
- United States
- Volunteers
- 800 people
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
Pituitary Adenoma 1, Acth-Secreting
Pituitary Adenoma and Serum Lipid
Pituitary adenomas are usually benign monoclonal neoplasms caused by a mixture of pituicyte alterations together with a changed endocrine and paracrine regulatory milieu.
- Trial name
- NCT04021212
- Where
- China
- Volunteers
- 1,000 people
- Sponsor
- Shandong Provincial Hospital
Cushing Syndrome
Extension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With Cushing Syndrome
This is an open-label extension study to evaluate the long-term safety of relacorilant in patients with endogenous Cushing syndrome who successfully completed participation in a Corcept-sponsored study of relacorilant and may…
- Trial name
- NCT03604198
- Testing
- relacorilant
- Where
- 48 sites in United States, Austria and 8 more
- Volunteers
- 125 people
- Sponsor
- Corcept Therapeutics
Cushing's Disease, Pituitary Adenoma
DDAVP for Pituitary Adenoma
This study is designed as a single institution trial. The study utilizes safe and clinically-validated tools for preoperative workup of patients with small pituitary tumors.
- Trial name
- NCT04569591
- Testing
- Desmopressin acetate
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
Acromegaly, Gigantism
Genetics of Endocrine Tumours - Familial Isolated Pituitary Adenoma - FIPA
The research is aimed at identifying new predisposition genes for endocrine tumours. Our focus initially is on pituitary adenomas including growth hormone-secreting tumors (somatotrophinomas) and prolactin secreting tumours…
- Conditions
- Acromegaly, Gigantism, Familial Isolated Pituitary Adenoma, FIPA
- Trial name
- NCT00461188
- Where
- 3 sites in United Kingdom
- Volunteers
- 10,000 people
- Sponsor
- Barts & The London NHS Trust
Pituitary Adenoma, Cushing Disease
Evaluation of Intraoperative Contrast Enhanced Ultrasound for the Identification of Pituitary Adenoma in Cushing's Disease Compared to Other Pituitary Tumors
This pilot and feasibility study aims to combine recent advances in ultrasound imaging, specifically an endonasal transducer array and contrast enhanced ultrasound, to offer an intraoperative image-guided solution for…
- Trial name
- NCT07335315
- Testing
- Contrast enhanced pituitary magnetic resonance imaging (MRI), Contrast enhanced ultrasound, Non-Contrast Ultrasound
- Where
- United States
- Volunteers
- 110 people
- Sponsor
- Mayo Clinic
Pituitary Adenomas
Genome-wide Association Study of Pituitary Tumors
Pituitary adenomas is a very common disease, but the cause and genetics hasn't been identified. The investigators are going to use genome-wide association study to identify genes that may be related to pituitary adenomas.
- Trial name
- NCT01442220
- Where
- China
- Volunteers
- 12,500 people, healthy volunteers welcome
- Sponsor
- Huashan Hospital
Panhypopituitarism, Gigantism/Acromegaly
An Investigation of Pituitary Tumors and Related Hypothalmic Disorders
There is a variety of tumors affecting the pituitary gland in childhood; some of these tumors (eg craniopharyngioma) are included among the most common central nervous system tumors in childhood.
- Conditions
- Panhypopituitarism, Gigantism/Acromegaly, Prolactinoma, Cushing Disease
- Trial name
- NCT00001595
- Testing
- Tissue specimen collection, MRI
- Where
- United States
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)